Iradimed Corp. (NASDAQ: IRMD) reported Q1 EPS of $0.49, $0.03 better than the analyst estimate of $0.46. Revenue for the quarter came in at $22 million versus the consensus estimate of $20.8 million.

GUIDANCE:

Iradimed Corp. sees Q2 2026 EPS of $0.44-$0.48, versus the consensus of $0.47. Iradimed Corp. sees Q2 2026 revenue of $20-21 million, versus the consensus of $21.13 million.

Iradimed Corp. sees FY2026 EPS of $2.06-$2.21, versus the consensus of $2.08. Iradimed Corp. sees FY2026 revenue of $91-96 million, versus the consensus of $102.8 million.

For earnings history and earnings-related data on Iradimed Corp. (IRMD) click here.